Prince Pharmaceutical (6935) Stock Overview
Manufactures and sells vitamin B1 active pharmaceutical ingredients (APIs) in Taiwan, Japan, Korea, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
6935 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Prince Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$30.90 |
| 52 Week High | NT$35.85 |
| 52 Week Low | NT$22.75 |
| Beta | 0.65 |
| 1 Month Change | 1.81% |
| 3 Month Change | 12.57% |
| 1 Year Change | 33.19% |
| 3 Year Change | -22.75% |
| 5 Year Change | n/a |
| Change since IPO | -42.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6935 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -1.4% | 1.3% | 4.3% |
| 1Y | 33.2% | -12.2% | 104.2% |
Return vs Industry: 6935 exceeded the TW Pharmaceuticals industry which returned -12.2% over the past year.
Return vs Market: 6935 underperformed the TW Market which returned 104.2% over the past year.
Price Volatility
| 6935 volatility | |
|---|---|
| 6935 Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in TW Market | 12.2% |
| 10% least volatile stocks in TW Market | 2.5% |
Stable Share Price: 6935 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6935's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1962 | 216 | Da Li | www.prince-pharm.com.tw |
Prince Pharmaceutical Co., Ltd. manufactures and sells vitamin B1 active pharmaceutical ingredients (APIs) in Taiwan, Japan, Korea, and internationally. The company also offers health food and medicines; vitamin c tablets, vitamin b complex tablets, natto and rhodiola extract capsules, probiotic sachets, and plant extract capsules; and API products comprising felbinac, aldioxa, tulobuterol, ufenamate, bisbentiamine, thiamine disulfide, potassium guaiacolsulfonate, potassium cresolsulfonate, fusultiamine hydrochloride, and fursultiamine. Prince Pharmaceutical Co., Ltd.
Prince Pharmaceutical Co., Ltd. Fundamentals Summary
| 6935 fundamental statistics | |
|---|---|
| Market cap | NT$1.13b |
| Earnings (TTM) | NT$96.32m |
| Revenue (TTM) | NT$1.06b |
Is 6935 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6935 income statement (TTM) | |
|---|---|
| Revenue | NT$1.06b |
| Cost of Revenue | NT$833.65m |
| Gross Profit | NT$222.55m |
| Other Expenses | NT$126.23m |
| Earnings | NT$96.32m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.63 |
| Gross Margin | 21.07% |
| Net Profit Margin | 9.12% |
| Debt/Equity Ratio | 35.4% |
How did 6935 perform over the long term?
See historical performance and comparisonDividends
Does 6935 pay a reliable dividends?
See 6935 dividend history and benchmarks| Prince Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Jul 01 2026 |
| Dividend Pay Date | Jul 28 2026 |
| Days until Ex dividend | 14 days |
| Days until Dividend pay date | 41 days |
Does 6935 pay a reliable dividends?
See 6935 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/16 23:27 |
| End of Day Share Price | 2026/06/16 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Prince Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.